The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1248 Weight Loss articles
India's pharma giants are in a fierce race to develop generic GLP-1 drugs like semaglutide following its patent expiry, amid soaring obesity rates affecting nearly a third of adults. One executive dubbed it a 'bloodbath' as demand surges. Eli Lilly's CEO highlighted oral pills as a key solution to global supply shortages.
The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?
In India, the GLP-1 rush is on—patients demand Ozempic or Mounjaro by name, generics slash costs to ₹1,290/month, fueled by Instagram and forums. But endocrinologists caution against indiscriminate use amid nausea, rebound weight, and serious risks. Inside the hype reshaping obesity treatment.
The pharmaceutical world is shifting: China has surged past the US in early-stage drug research, with programs jumping over 600% since 2015. This rapid growth promises cheaper, innovative treatments like advanced obesity drugs potentially better than Ozempic—but raises questions on access and geopolitics for patients worldwide.
Popular drugs like semaglutide and tirzepatide are transforming weight loss for type 2 diabetes and obesity patients. But a new UNC study warns of hidden muscle loss that could impact strength and mobility. Here's what the research means for safe, healthy weight management.
Peptides are surging in popularity among influencers and biohackers for everything from injury recovery to youthful skin, but the science lags far behind the hype. With FDA bans on key ones like BPC-157 and potential changes ahead, here's what you need to know about their evidence, safety, and gray-market realities.
Tapatío hot sauce, a Southern California favorite, is gaining traction among GLP-1 users battling taste loss from drugs like Ozempic and Wegovy. Private equity firm Highlander Partners acquired the brand to capitalize on this trend, as spicy heat invigorates dulled taste buds. Experts explain the science behind GLP-1 taste changes and offer hope for recovery.
Social media is spotlighting GLP-1 receptor agonist side effects that clinical trials overlooked, according to a new study in Nature Health. Researchers sifted through 410,198 Reddit posts on semaglutide and tirzepatide, finding 43.5% of users reporting issues like nausea and fatigue. These insights reveal patient concerns beyond traditional data.
While most people on GLP-1 medications like Wegovy experience significant weight loss, 10-15% are non-responders. Emerging research shows these drugs still improve liver health, reduce heart risks, and more—independent of weight changes. A new mouse study reveals why, challenging insurance requirements for weight loss thresholds.
